By the end of the year, a British biotech plans to start testing a new kind of cell therapy based on macrophages, a roaming immune …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Noting that the term “nonalcoholic fatty liver disease” (NAFLD) is stigmatizing, an international group of medical organizations proposed a name change to “metabolic dysfunction-associated steatotic
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Massimo Calafiore, new Orthofix CEO Courtesy of